ERBB2 and breast neoplasm: In the area of PET imaging, the median progression-free survival of patients with estrogen receptor (ERe)- positive, human epithelial growth factor 2 (HER2)- negative breast tumours undergoing endocrine therapy was linked to their FDG uptake prior to treatment [11].